Ono Pharmaceutical Co., Ltd.

4528.T
Drug Manufacturers - General
2026/10/29 11:49 Updated
Market Cap: $7.4B (¥1.2T)
Stock Price: $15.69 (¥2,479)
Exchange Rate: 1 USD = ¥157.98

Supplementary Financial Materials (Interim Consolidated Results for the Fiscal Year Ending March 2027 (Core Basis))

Published interim consolidated results (core basis) and consolidated earnings forecast for the fiscal year ending March 2027. Revenue is 455.0 hundred million yen, down 11.8% year-over-year; core operating income is 124.0 hundred million yen (down 9.6% year-over-year); core net income attributable to owners of parent is 93.0 hundred million yen (down 10.1% year-over-year). Product sales are expected to decline, while royalties and other revenue are expected to increase. Research and development investment will continue.

Importance:
Page Updated: October 29, 2026
IR Disclosure Date: October 29, 2026

Key Figures

  • Revenue: 4,550 hundred million yen (Down 11.8% YoY)
  • Core Operating Income: 1,240 hundred million yen (Down 9.6% YoY)
  • Core Net Income Attributable to Owners of Parent: 930 hundred million yen (Down 10.1% YoY)

AI要約

Overview of Results

With the publication of interim consolidated results and full-year forecasts, revenue is expected to be 4,550 hundred million yen (down 11.8% year-over-year), core operating income is expected to be 1,240 hundred million yen (down 9.6% year-over-year), and core net income is expected to be 930 hundred million yen (down 10.1% year-over-year). Primary factors include anticipated decreases in domestic and overseas product sales and the impact of the termination of co-promotion agreements, while royalties and other income are expected to increase. Research and development investment will continue to be actively pursued.

Business and Investment Trends and Outlook

To offset the decrease in product sales, an increase in royalty income is anticipated, and total revenue is forecast at 4,550 hundred million yen. To limit declines in core metrics, the company plans to continue R&D investment while strengthening cost management. The number of employees in the interim period is 4,206 (interim basis), and year-end staffing trends will be monitored.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Ono Pharmaceutical Co., Ltd.

Company overview · Stock price · Financial data · All IR

View company page →